[go: up one dir, main page]

MX2016015627A - Compuesto de tiazolidinona y su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación. - Google Patents

Compuesto de tiazolidinona y su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación.

Info

Publication number
MX2016015627A
MX2016015627A MX2016015627A MX2016015627A MX2016015627A MX 2016015627 A MX2016015627 A MX 2016015627A MX 2016015627 A MX2016015627 A MX 2016015627A MX 2016015627 A MX2016015627 A MX 2016015627A MX 2016015627 A MX2016015627 A MX 2016015627A
Authority
MX
Mexico
Prior art keywords
psychiatric
inflammation
treatment
neurological disorders
neuroinflamation
Prior art date
Application number
MX2016015627A
Other languages
English (en)
Other versions
MX378165B (es
Inventor
Louis Reymond Jean-
NICOLUSSI Simon
Gertsch Jürg
Original Assignee
Universität Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Bern filed Critical Universität Bern
Publication of MX2016015627A publication Critical patent/MX2016015627A/es
Publication of MX378165B publication Critical patent/MX378165B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La invención se refiere a un compuesto que comprende la siguiente formula general (1) y a dicho compuesto para su uso como un medicamento, en particular para su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación: (ver Fórmula) en la que cada uno de R1, R2 y R3 se selecciona independientemente uno de otro entre alquilo, alcoxi, alquenilo, alquinilo, cicloalquilo, arilo, heterociclo o heteroarilo.
MX2016015627A 2014-05-28 2015-05-28 Compuesto de tiazolidinona y su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación. MX378165B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170449 2014-05-28
EP14171024 2014-06-03
PCT/EP2015/061915 WO2015181337A1 (en) 2014-05-28 2015-05-28 Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

Publications (2)

Publication Number Publication Date
MX2016015627A true MX2016015627A (es) 2017-05-04
MX378165B MX378165B (es) 2025-03-10

Family

ID=54698145

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015627A MX378165B (es) 2014-05-28 2015-05-28 Compuesto de tiazolidinona y su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación.
MX2020013537A MX2020013537A (es) 2014-05-28 2016-11-28 Compuestos de tiazolidinona y su uso en el tratamiento de trastornos psiquiatricos o neurologicos y de la inflamacion, en particular de la neuroinflamacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013537A MX2020013537A (es) 2014-05-28 2016-11-28 Compuestos de tiazolidinona y su uso en el tratamiento de trastornos psiquiatricos o neurologicos y de la inflamacion, en particular de la neuroinflamacion.

Country Status (15)

Country Link
US (3) US10155754B2 (es)
EP (2) EP3148990B1 (es)
JP (1) JP6671301B2 (es)
CN (1) CN106660976B (es)
AU (2) AU2015265865C1 (es)
BR (1) BR112016027901B1 (es)
CA (1) CA2950354C (es)
DK (1) DK3148990T3 (es)
ES (1) ES2910455T3 (es)
HR (1) HRP20220490T8 (es)
MX (2) MX378165B (es)
PL (1) PL3148990T3 (es)
RS (1) RS63107B1 (es)
RU (1) RU2734253C2 (es)
WO (1) WO2015181337A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300048B2 (en) * 2014-05-28 2019-05-28 Universitat Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
WO2024240779A1 (en) 2023-05-19 2024-11-28 Universität Bern A binding site to prevent endocannabinoid cellular reuptake

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798067A (en) * 1954-03-29 1957-07-02 Eastman Kodak Co 2-imino-4-thiazolidones and preparation
US2739888A (en) * 1954-03-29 1956-03-27 Eastman Kodak Co Photographic elements containing thiazolidine derivatives
ATE411302T1 (de) * 2002-11-22 2008-10-15 Smithkline Beecham Corp Thiazolidin-4-ones um hyak3 proteinen zu hemmen
EP1660459A2 (en) * 2003-08-12 2006-05-31 Amgen inc. Arylsulfonamidobenzylic compounds
US20050042213A1 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
ES2352555T3 (es) * 2003-11-21 2011-02-21 Actelion Pharmaceuticals Ltd. Derivados de 5-(benc-(z)-iliden)tiazolidin-4-ona como agentes inmunosupresores.
JP5199108B2 (ja) * 2005-11-14 2013-05-15 ユニヴァーシティー オブ サザン カリフォルニア インテグリン結合小分子
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2009137133A2 (en) * 2008-02-14 2009-11-12 University Of Washington 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection
ES2557314T3 (es) 2009-05-29 2016-01-25 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Dodeca-2E,4E-dieno amidas y sus usos como medicamentos y cosméticos
GB201007187D0 (en) * 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators

Also Published As

Publication number Publication date
AU2015265865A1 (en) 2016-12-15
RU2016147230A (ru) 2018-07-02
CA2950354C (en) 2023-10-03
AU2020213369A1 (en) 2020-08-27
US20190382397A1 (en) 2019-12-19
JP6671301B2 (ja) 2020-03-25
CN106660976B (zh) 2019-11-26
US10392377B2 (en) 2019-08-27
US20190119265A1 (en) 2019-04-25
US20170197952A1 (en) 2017-07-13
DK3148990T3 (da) 2022-04-11
WO2015181337A1 (en) 2015-12-03
HRP20220490T1 (hr) 2022-05-27
ES2910455T3 (es) 2022-05-12
RS63107B1 (sr) 2022-04-29
BR112016027901A2 (pt) 2017-08-22
PL3148990T3 (pl) 2022-05-30
MX378165B (es) 2025-03-10
RU2734253C2 (ru) 2020-10-13
JP2017516795A (ja) 2017-06-22
HRP20220490T8 (hr) 2022-06-10
CA2950354A1 (en) 2015-12-03
EP3148990A1 (en) 2017-04-05
AU2015265865B2 (en) 2020-05-07
RU2016147230A3 (es) 2018-12-25
EP3148990B1 (en) 2022-01-19
AU2015265865C1 (en) 2025-01-30
EP4011879A1 (en) 2022-06-15
MX2020013537A (es) 2021-02-26
CN106660976A (zh) 2017-05-10
AU2020213369B2 (en) 2022-09-22
US10774077B2 (en) 2020-09-15
US10155754B2 (en) 2018-12-18
BR112016027901B1 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2017000450A (es) Compuestos terapeuticos inhibidores.
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
MX393838B (es) Uso de compuestos heterociclicos para controlar nematodos.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
MX381417B (es) Inhibidores de glucosidasa.
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
GT201500334A (es) Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo
PT3220916T (pt) Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida
MX2017000330A (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CR20170247A (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
CR20160459A (es) Nuevos derivados de piridina
CR20160448A (es) Nuevos derivados de piridina
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.